Literature DB >> 25132630

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium.

Ola Landgren1, Nicole Gormley, Danielle Turley, Roger G Owen, Andy Rawstron, Bruno Paiva, David Barnett, Maria Arroz, Paul Wallace, Brian Durie, Constance Yuan, Ahmet Dogan, Maryalice Stetler-Stevenson, Gerald E Marti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25132630     DOI： 10.1002/ajh.23831

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  25 in total

Review 1.  New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.

Authors:  Ola Landgren; S Vincent Rajkumar
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

2.  Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.

Authors:  Enrico Caserta; Junie Chea; Megan Minnix; Erasmus K Poku; Domenico Viola; Steven Vonderfecht; Paul Yazaki; Desiree Crow; Jihane Khalife; James F Sanchez; Joycelynne M Palmer; Susanta Hui; Nadia Carlesso; Jonathan Keats; Young Kim; Ralf Buettner; Guido Marcucci; Steven Rosen; John Shively; David Colcher; Amrita Krishnan; Flavia Pichiorri
Journal:  Blood       Date:  2018-01-04       Impact factor: 22.113

3.  Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma.

Authors:  Jeffrey Lee Jensen; Alexander Rakhmilevich; Erika Heninger; Aimee Teo Broman; Chelsea Hope; Funita Phan; Shigeki Miyamoto; Ioanna Maroulakou; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Paul Sondel; Fotis Asimakopoulos
Journal:  Cancer Immunol Res       Date:  2015-05-04       Impact factor: 11.151

Review 4.  Minimal residual disease testing after stem cell transplantation for multiple myeloma.

Authors:  A M Sherrod; P Hari; C A Mosse; R C Walker; R F Cornell
Journal:  Bone Marrow Transplant       Date:  2015-07-20       Impact factor: 5.483

Review 5.  New criteria for response assessment: role of minimal residual disease in multiple myeloma.

Authors:  Bruno Paiva; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2015-04-02       Impact factor: 22.113

6.  Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

Authors:  Neha Korde; Mark Roschewski; Adriana Zingone; Mary Kwok; Elisabet E Manasanch; Manisha Bhutani; Nishant Tageja; Dickran Kazandjian; Sham Mailankody; Peter Wu; Candis Morrison; Rene Costello; Yong Zhang; Debra Burton; Marcia Mulquin; Diamond Zuchlinski; Liz Lamping; Ashley Carpenter; Yvonne Wall; George Carter; Schuyler C Cunningham; Verena Gounden; Tristan M Sissung; Cody Peer; Irina Maric; Katherine R Calvo; Raul Braylan; Constance Yuan; Maryalice Stetler-Stevenson; Diane C Arthur; Katherine A Kong; Li Weng; Malek Faham; Liza Lindenberg; Karen Kurdziel; Peter Choyke; Seth M Steinberg; William Figg; Ola Landgren
Journal:  JAMA Oncol       Date:  2015-09       Impact factor: 31.777

Review 7.  Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.

Authors:  Jonathan J Hogan; Brendan M Weiss
Journal:  Clin J Am Soc Nephrol       Date:  2016-07-14       Impact factor: 8.237

Review 8.  Minimal residual disease in multiple myeloma: bringing the bench to the bedside.

Authors:  Sham Mailankody; Neha Korde; Alexander M Lesokhin; Nikoletta Lendvai; Hani Hassoun; Maryalice Stetler-Stevenson; Ola Landgren
Journal:  Nat Rev Clin Oncol       Date:  2015-01-27       Impact factor: 66.675

Review 9.  Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Joseph D Tario; Paul K Wallace
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

10.  Should minimal residual disease negativity not be the end point of myeloma therapy?

Authors:  Pieter Sonneveld
Journal:  Blood Adv       Date:  2017-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.